SS Innovations International Inc is a commercial-stage surgical robotics company. It designs, manufactures, and markets a surgical robotic system called the SSi Mantra Surgical Robotic System (the SSi Mantra) intended for use in urology, general, gynecology, colorectal, gastroenterology, head and neck, thoracic, and cardiac surgeries. Additionally, the company offers a suite of stapling, energy, and core instrumentation for its surgical systems, under the brand name of SSi Mudra.
Last trade$1.30
Day change-$0.05 (-3.70%)
Day range$1.05 – $1.38
Volume224,542
Market cap$271M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$270.66M
Price / earnings
—
Price / book
5.07×
Price / sales
5.16×
EV / sales
5.18×
EV / EBITDA
-54.05×
Profitability
Earnings per share
-$0.06
Return on assets
-12.82%
Return on equity
-23.28%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.27×
Current ratio
2.24×
Quick ratio
1.66×
Cash ratio
0.43×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$18.22M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SSII, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Revenue
$13.94M
$11.1M
$14.53M
$12.83M
$10M
Cost of revenue
$6.84M
$5.77M
$8.16M
$6.66M
$4.09M
Gross profit
$7.1M
$5.33M
$6.38M
$6.16M
$5.92M
Selling, general and administrative
$4.45M
$4.5M
$5.41M
$6.92M
$3.43M
Research and development
$2.4M
$995.44K
$1.39M
$786.32K
$498.6K
Total operating expenses
$7.19M
$8.97M
$7.11M
$8M
$4.19M
Operating income
-$93.2K
-$3.64M
-$735K
-$1.84M
$1.73M
Interest expense
-$344.76K
-$284.05K
-$335.3K
-$176.64K
-$216.8K
Income before taxes
-$2.16M
-$3.43M
-$705.73K
-$1.87M
$97.04K
Income taxes
$505.28K
$151.35K
$1.77M
$1.85M
$353.73K
Net income
-$2.66M
-$3.58M
-$2.47M
-$3.72M
-$256.69K
Net income attributable to common shareholders
-$2.66M
-$3.58M
-$2.47M
-$3.72M
-$256.69K
EBITDA
$253.17K
-$3.32M
-$425.51K
-$1.54M
$1.99M
Basic earnings per share
-$0.01
-$0.02
-$0.01
-$0.02
$0.00
Diluted earnings per share
-$0.01
-$0.02
-$0.01
-$0.02
$0.00
Recent news
Company coverage with links to the original publishers.
SS Innovations International (SSII) has seen its stock decline 31.8% over three months amid widening losses, mounting operating expenses, and cash burn concerns. While the company benefits from growing adoption of its robotic surgery systems and expanding global presence, persistent profitability challenges, liquidity constraints, and heavy geographic concentration in India (93% of revenues) remain significant headwinds. The company trades at a premium valuation of 8.64X EV/sales compared to the industry average of 2.78X.
The article profiles two rare microcap companies generating majority sales outside the US: SS Innovations International (SSII), a surgical robotics company with 87% of sales from India showing strong 39.4% YOY revenue growth but facing cash burn issues, and Iveda Solutions (IVDA), an AI-driven smart city technology provider with 91% of sales from Taiwan that generates lumpy, project-driven revenue from government contracts.
Zacks Investment Research initiated coverage of SS Innovations International (SSII) with a Neutral recommendation. The surgical robotics company shows strong growth in system installations (up 42% to 238 units) and procedure volumes (up 79% to 14,103), with revenues increasing to $25 million in H1 2026. However, persistent operating losses of $6.2 million, financing needs, regulatory uncertainties, and competition from established manufacturers temper the outlook.
SS Innovations International, Inc. (Nasdaq: SSII) announced the appointment of Milan Rao as Global Chief Operating Officer and Chief Financial Officer, a newly created position. Rao, who brings over three decades of executive leadership experience in technology-enabled transformation and operations at global companies including healthcare sector roles, will succeed Naveen Kumar Amar as CFO. The appointment reflects the company's commitment to expanding the global footprint of its SSi Mantra surgical robotic system.
Three emerging technology companies are positioned for potential growth: Navitas Semiconductor in power semiconductors, SS Innovations in surgical robotics, and Vertical Aerospace in electric vertical takeoff and landing aircraft, each facing significant technological and market challenges.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.